ライフサイエンスコーパス: plasma concentration

1 0 and increased follicle-stimulating hormone plasma concentration.

2 not necessarily lead to high in vivo unbound plasma concentration.

3 on of erlotinib, without affecting erlotinib plasma concentration.

4 ection when reaching or exceeding a critical plasma concentration.

5 fluorescein angiography, CBCs, and melphalan plasma concentration.

6 with i.v. delivery with substantially lower plasma concentrations.

7 diet diary estimates of vitamin C intake and plasma concentrations.

8 n elevation of IL13 levels and decreased IL6 plasma concentrations.

9 ite all subjects achieving target nifedipine plasma concentrations.

10 s to be below the level of human therapeutic plasma concentrations.

11 ing outcomes were correlated with dabigatran plasma concentrations.

12 s experienced potentially toxic piperacillin plasma concentrations.

13 asing fatty acid chain length and the target plasma concentrations (0.5-1.0ng/mL over a month-long pe

14 n glucuronide reach peak nanomolar per liter plasma concentrations 1.6-2.3 h after intake, indicating

15 ile the zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective ad

16 rinogen on the zeolite nanoparticles at high plasma concentration (100%) was observed.

17 up displayed marked increases in DHA and EPA plasma concentrations (2.6- and 3.5-fold), as well as de

18 nd a pharmacokinetics study documents a peak plasma concentration 30 min after dosing, with the agent

19 CXCL9 plasma concentrations above the median were associated w

20 splant center (n = 211) confirmed that CXCL9 plasma concentrations above the median were associated w

21 GSK744 LA, at plasma concentrations achievable with quarterly injectio

22 rd doses of ART achieved higher genital than plasma concentrations across the menstrual cycle.

23 Whereas plasma concentrations/activities of key coagulation/fibr

24 recommended dose of 1500 mg BID may achieve plasma concentrations adequate to treat TE in HIV-infect

25 mine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK

26 In vivo, the peak plasma concentration and area under the concentration ti

27 n had minimal impact on DRV maximum observed plasma concentration and area under the curve; DRV Ctrou

28 Unbound piperacillin plasma concentration and fractional time of plasma conce

29 The plasma concentration and urinary excretion of naringenin

30 We compared the plasma concentrations and clearance rates of four solute

31 rmally cleared by tubular secretion with the plasma concentrations and clearance rates of urea and cr

32 tal muscle in relation to dietary intake and plasma concentrations and compared this relation with as

33 oncentrations in CSF were similar to unbound plasma concentrations and exceeded the in vitro 50% inhi

34 roprotein convertase subtilisin/kexin type 9 plasma concentrations and fatty acid compositions did no

35 We generated a qAOP network based on drug plasma concentrations and focused on immunodepression, s

36 ely correlated with proinflammatory cytokine plasma concentrations and had lower surface IgG levels t

37 Splenic Th9 and Th17 cells, plasma concentrations and liver expression of IL-9 and I

38 us Abdominis Plane blocks can result in high plasma concentrations and local anesthetic systemic toxi

39 een brain-derived neurotrophic factor (BDNF) plasma concentrations and the BDNF Val66Met nucleotide p

40 We correlated edoxaban dose, plasma concentration, and anti-Factor Xa (FXa) activity

41 tential, binding potential relative to total plasma concentration, and binding potential relative to

42 Parent, radiometabolite fractions, plasma concentration, and cerebellar uptake of (18)F-FE-

43 nsic clearance leads to high in vivo unbound plasma concentration, and low efflux transport activity

44 circulating ghrelin levels, increased GLP-1 plasma concentration, and remodeling of gut microbiome d

45 Concomitant LPV/r use markedly increased TFV plasma concentrations, and AUC0-48 h was 67% higher with

46 tigate the impact of ticagrelor on adenosine plasma concentration (APC) in acute coronary syndrome (A

47 we introduce the "cortisol equivalents fish plasma concentration" approach, through which an increas

48 However, in our study isradipine plasma concentrations approved for therapy were not neur

49 m/magnesium administration may be helpful if plasma concentrations are low.

50 Sofosbuvir is orally administered, and peak plasma concentrations are not affected by food.

51 ELISA and INAA we report the half-life, peak plasma concentrations, area under the curve, ability to

52 well as 2) pretreatment tHcy and 3) albumin plasma concentrations as being significant contributors

53 that accounted well for the time profiles of plasma concentrations as well as effects on tremor sever

54 l dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac f

55 he plasma concentration-time curve (AUC) and plasma concentration at 12 hours after intake (C12h) pla

56 ge, initial parasite density, or piperaquine plasma concentrations at 7 days.

57 e more likely to have detectable piperaquine plasma concentrations at baseline compared with non-recr

58 We measured piperaquine plasma concentrations at baseline, 7 days, and day of re

59 tion, and binding potential relative to free plasma concentration: BPND, BPP, BPF, respectively).

60 fenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir dis

61 vel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-tar

62 We tested vitamin B-12 plasma concentrations by using chemiluminescent competit

63 ed in a significant increase in mean maximum plasma concentration (C max ), elimination half-life and

64 ntration-time curve (AUC)(0-12h) and maximum plasma concentration (C(max)) for raltegravir + boceprev

65 Antiretroviral trough plasma concentrations (C12h) were determined using liqui

66 of the study through a comparison of maximum plasma concentration (Cmax) and area under the concentra

67 Maximum plasma concentration (Cmax) and area under the concentra

68 o free lutein, PLGA-NP increased the maximal plasma concentration (Cmax) and area under the time-conc

69 The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL an

70 on versus time curve (AUC), maximum observed plasma concentration (Cmax), and time above a threshold

71 id (63% and 70% lower geometric mean maximum plasma concentration [Cmax] and 77% and 82% lower AUC0-t

72 ion modeling, the egg intervention increased plasma concentrations compared with control by the follo

73 peaked before d6-alpha-T in 77 of 80 paired plasma concentration curves.

74 The in vivo time versus plasma concentration data of three estradiol TDDS at dru

75 In women (n = 12), motilin (P = 0.04) plasma concentrations decreased after intragastric DB ad

76 proximately 5 muM) approximating its unbound plasma concentration (determined by equilibrium dialysis

77 Infant plasma concentrations did not change significantly durin

78 Maximum plasma concentrations, dose-proportional to 800 mg, occu

79 fore each weekly VRE session, to ensure peak plasma concentrations during the sessions in 25 patients

80 s showed that high-dose methotrexate maximum plasma concentration (estimate = 0; P = .48), median cle

81 en though the compounds reached steady state plasma concentrations exceeding their Ki values by >60-f

82 2) Anandamide plasma concentrations exhibited no differences in their

83 who are at the highest risk of unpredictable plasma concentration exposing them to overdose, toxicity

84 from time zero to last sampling and maximum plasma concentration exposure with short half-life (rang

85 avenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap t

86 avenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap t

87 ood containing the peak, midpoint, or trough plasma concentrations for meropenem, ceftolozane-tazobac

88 doses from breast milk and resultant infant plasma concentrations for tenofovir and emtricitabine we

89 e contractility assays over paroxetine and a plasma concentration higher than its IC50 for over 7 h.

90 interdigestive motility, motilin and ghrelin plasma concentrations, hunger and satiety ratings, and f

91 The plasma concentration in humans was quantified in patient

92 , giving the conversion formula: (creatinine plasma concentration in mumol/L) = (creatinine concentra

93 We investigated the determinants of sST2 plasma concentrations in 2,991 Framingham Offspring Coho

94 rapy (cART) impacted steady-state atovaquone plasma concentrations in human immunodeficiency virus (H

95 k, but there was an inverse association with plasma concentrations in men, with quintile 4 having sig

96 corroborated by increased insulin and IGF-1 plasma concentrations in multiple system atrophy patient

97 tose 1-phosphate (0.1 mM), (corresponding to plasma concentrations in patients on galactose-restricte

98 ral bioavailability (F = 50%) and sufficient plasma concentrations in rats, providing an excellent st

99 oncentration at 12 hours after intake (C12h) plasma concentrations in the third trimester were on ave

100 formance as a function of its measured blood plasma concentration: it reduced reflection impulsivity

101 The unlabeled drug dose and plasma concentration leading to a 50% reduction of (11)C

102 he in vivo efficacy correlated well with the plasma concentration levels, and no acute toxicity sympt

103 transplantation (LT), immunoglobulin (Ig) G plasma concentrations<6 g/L are common and correlate wit

104 nal probrain natriuretic peptide (NT-proBNP) plasma concentrations (median 1904 pg/mL).

105 The highest plasma concentration observed (for fish exposed to 25 mu

106 to note that the area under the curve of the plasma concentration of (-)-epicatechin metabolites over

107 ich the methylxanthines mediate an increased plasma concentration of (-)-epicatechin metabolites that

108 omplex, with subsequent determination of the plasma concentration of 25-hydroxy-D3.

109 . in amyloid positive controls, SCD and MCI) plasma concentration of Abeta42 was just moderately decr

110 study was to determine whether a physiologic plasma concentration of alpha-ketoglutarate (alphaKG) in

111 Plasma concentration of ApoA4, a major HDL-C protein fra

112 The mean +/- SD plasma concentration of betaine was 13.2 +/- 2.7 mumol/L

113 ct of posture on blood pressure, heart rate, plasma concentration of catecholamines, vasopressin, end

114 pon peroral dosing to rodents led to maximum plasma concentration of CsA at 6 h as opposed to 24 h wi

115 In mice not treated with exogenous tPA, the plasma concentration of endogenous tPA increased 3-fold

116 In critically ill patients, plasma concentration of ghrelin significantly differs fr

117 olymorphism has been associated with a lower plasma concentration of holotranscobalamin.

118 Despite this, there was no difference in plasma concentration of IL-6 at baseline versus 24 (P =

119 This influenced plasma concentration of inflammatory cytokines and key m

120 e primary endpoint was the difference in the plasma concentration of interleukin-6 (IL-6) 24 and 48 h

121 status, insulin sensitivity, glucose uptake, plasma concentration of isoprostanes, and total antioxid

122 An elevated plasma concentration of lipopolysaccharide (LPS) caused

123 It has long been known that the plasma concentration of Lp(a) is highly heritable, with

124 A higher plasma concentration of methotrexate was associated with

125 Higher plasma concentration of methotrexate was associated with

126 XR-knockout mice on a high-protein diet, the plasma concentration of newly formed urea was significan

127 A chronically high plasma concentration of SAA results in the aggregation o

128 ptor CXCR4 correlated significantly with the plasma concentration of the CXCR4 ligand, CXCL12.

129 found higher in HS rats despite no change in plasma concentration of these ions.

130 Lastly, the plasma concentration of TSP-1 is significantly increased

131 es of kPhd2KO mice, accompanied by increased plasma concentration of vascular endothelial growth fact

132 mice, the addition of elacridar (at systemic plasma concentrations of >/=200 ng/mL) resulted in an in

133 d given injections of 1,25(OH)2D3, liver and plasma concentrations of 1,25(OH)2D3 increased and decre

134 significantly affecting extracellular pH or plasma concentrations of 1,25(OH)2D3, Ca(2+), and phosph

135 We measured plasma concentrations of 105 metabolites using targeted

136 out cetrimide (5%, w/w)) resulted in average plasma concentrations of 2.6-16.2nM between 2 and 6h, wh

137 Plasma concentrations of 200 proteins changed significan

138 We measured baseline fasting plasma concentrations of 23 metals and used conditional

139 We here determined arterial plasma concentrations of 25 different cytokines, growth

140 Increased plasma concentrations of 25(OH)D might reduce the risk o

141 We tested the hypothesis that low plasma concentrations of 25-hydroxyvitamin D are associa

142 Furthermore, plasma concentrations of 3-hydroxykynurenine paralleled

143 e intake significantly elevated mean +/- SEM plasma concentrations of 8 flavanone (1.75 +/- 0.35 mumo

144 a standardized breakfast was consumed, with plasma concentrations of acylated ghrelin, glucagon-like

145 GFT505 treatment decreased plasma concentrations of alanine aminotransferase, gamma

146 To test this, we measured plasma concentrations of albumin, total proteins.

147 Plasma concentrations of all gut barrier biomarkers and

148 Plasma concentrations of amino acids (AAs), in particula

149 Baseline urinary F2-isoprostanes, plasma concentrations of antioxidant micronutrients (toc

150 xamined associations of baseline (1993-1997) plasma concentrations of apoC-III and subspecies of HDL

151 t BMI x genotype interactions for changes in plasma concentrations of arachidonic acid and DHA in pho

152 introduced early in complementary feeding on plasma concentrations of biomarkers in choline pathways,

153 tail skin temperatures) of rats, even though plasma concentrations of both antagonists well exceeded

154 h volunteer; meal 1 was designed to increase plasma concentrations of both TGRLs and nonesterified fa

155 Fasting plasma concentrations of C-reactive protein and IL-6 did

156 als (CIs) comparing the extreme quartiles of plasma concentrations of C16:0, C22:0, C24:0, and C24:1

157 e cardiovascular system have been related to plasma concentrations of carotenoids.

158 Secondary outcomes included plasma concentrations of CF-derived metabolites and meth

159 chemiluminescent competitive immunoassay and plasma concentrations of choline, betaine, dimethylglyci

160 Differential plasma concentrations of circulating lipid species are a

161 Plasma concentrations of collagen type 1 cross-linked C-

162 In a pre-specified analysis of RE-LY, plasma concentrations of dabigatran were determined in p

163 Female plasma concentrations of E2 and vitellogenin increase in

164 Our results demonstrate that plasma concentrations of EBOV are markedly different bet

165 Peak plasma concentrations of elamipretide occurred at end-in

166 Transpulmonary thermodilution-based EVLWi, plasma concentrations of epithelial (soluble receptor fo

167 reduced fetal weights by 13%, lowered fetal plasma concentrations of essential amino acids, and decr

168 e or a dose-matched hesperidin supplement on plasma concentrations of established and novel flavanone

169 l clots, is higher than that in gels made at plasma concentrations of fibrinogen (3-10 mg/mL), where

170 008) with measured first pregnancy trimester plasma concentrations of four PFASs (in nanograms/millil

171 Plasma concentrations of free choline, betaine, and phos

172 cantly increases satiety but does not affect plasma concentrations of GLP-1 and PYY.

173 Plasma concentrations of glyoxal are elevated in in diab

174 High plasma concentrations of homocysteine are assumed to be

175 of 15-yr-old children (n= 324), we measured plasma concentrations of homocysteine, choline, and beta

176 no significant intergroup difference in the plasma concentrations of IL-1beta, -8, -10, or -12 p70 o

177 Briefly, plasma concentrations of IL-1RA, IL-6, IL-8, IL-15, eota

178 d meat intake is associated with unfavorable plasma concentrations of inflammatory and glucose metabo

179 henotype 2) that was characterised by higher plasma concentrations of inflammatory biomarkers, a high

180 Fasting plasma concentrations of insulin increased by 120% +/- 1

181 Mean plasma concentrations of insulin, C-peptide, glucagon, a

182 over 4 hours using MRI and blood glucose and plasma concentrations of insulin, peptide YY, and ghreli

183 ter syndrome-like phenotype, including lower plasma concentrations of K+ and H+ and compensatory upre

184 went peripheral venous sampling to determine plasma concentrations of key collagen precursors (procol

185 Mood scales and plasma concentrations of kynurenine metabolites were ass

186 ndividuals displayed significantly increased plasma concentrations of LPCs containing mono- and polyu

187 otoxic events were accompanied by changes in plasma concentrations of macrophage-derived cytokine, eo

188 ty was evaluated using clinical outcomes and plasma concentrations of markers of inflammation, glucos

189 h ophthalmic issues had significantly higher plasma concentrations of metabolites that are associated

190 Elevated serum and plasma concentrations of MMP-8 are associated with the r

191 Plasma concentrations of N- terminal pro-B-type natriure

192 Plasma concentrations of natriuretic peptides decline wi

193 ction fraction </=40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were rando

194 inhibition of fractional DNL associated with plasma concentrations of NDI-010976 >4 ng/mL.

195 igh-risk individuals, we quantified baseline plasma concentrations of nine PFAS among 957 participant

196 High plasma concentrations of nonesterified fatty acids (NEFA

197 type 2 diabetes is inversely correlated with plasma concentrations of odd-chain fatty acids [OCFAs; p

198 Plasma concentrations of omega-3 (omega-3) fatty acids a

199 utic doses of ritonavir are used to increase plasma concentrations of other HIV drugs oxidized by CYP

200 No correlation was observed with plasma concentrations of p,p'-dichlorodiphenyl dichloroe

201 Plasma concentrations of PL 5'-phosphate (PLP), which is

202 We measured plasma concentrations of plasminogen activator inhibitor

203 que, and parasite biomass was estimated from plasma concentrations of Plasmodium falciparum histidine

204 and insulin-resistant subjects have elevated plasma concentrations of pro-NT, and in longitudinal stu

205 gal Candida species in the gut and increased plasma concentrations of prostaglandin E(2) (PGE(2)), wh

206 Plasma concentrations of protein unbound, total RAL, and

207 aimed to measure and validate differences in plasma concentrations of proteins that are associated wi

208 Low plasma concentrations of pyridoxal 5'-phosphate (PLP) ar

209 on, it is crucial to extend the knowledge on plasma concentrations of reactive key alpha-dicarbonyl c

210 The plasma concentrations of several biomarkers are either p

211 Elevated plasma concentrations of small dense LDL (sdLDL) correla

212 Elevated plasma concentrations of soluble VEGFA isoforms are asso

213 We compared plasma concentrations of SPMs in men and women with feat

214 The plasma concentrations of tanshinones were detected by a

215 sis of prior monkey studies, we suspect that plasma concentrations of tariquidar did not fully block

216 Performing (11)C-dLop PET during peak plasma concentrations of tariquidar, achieved with concu

217 ingested with a meal, by pill count, and by plasma concentrations of tenofovir and FTC at week 4); a

218 or repeated measures) lowered postabsorptive plasma concentrations of tHcy by -11.7% +/- 3.0% (placeb

219 sma AnxA1 was also inversely correlated with plasma concentrations of the acute-phase protein, C-reac

220 a highly sensitive IL-2 assay, the observed plasma concentrations of the drug at 90 min exceeded the

221 Elevated plasma concentrations of the gut bacteria choline metabo

222 Peripheral plasma concentrations of the gut hormones GLP-1, GIP, PY

223 tions were not accompanied by changes in the plasma concentrations of the gut-derived peptides cholec

224 release was achieved via NIR laser light and plasma concentrations of the model drug were determined

225 Plasma concentrations of the modified analogue, PYY-AP3H

226 Furthermore, mice lacking Sarm1 had reduced plasma concentrations of the phophorylated axonal neurof

227 Volunteers with MetS had reduced plasma concentrations of the precursors of the E- and D-

228 Higher plasma concentrations of the vitamin B-6 marker pyridoxa

229 and rare (MAF <0.01) variants that influence plasma concentrations of these 4 hemostatic factors by m

230 bit different modulations in salivary and/or plasma concentrations of these parameters compared with

231 rotein (HDL), low-density lipoprotein (LDL), plasma concentrations of total cholesterol (TC) and trig

232 At baseline E4 carriers had higher plasma concentrations of total cholesterol (TC), low-den

233 ween the dose of quercetin-3-O-glucoside and plasma concentrations of total quercetin (R(2) = 0.52, P

234 Plasma concentrations of triglycerides were measured imm

235 Plasma concentrations of trimethylamine, TMAO, choline,

236 ence of arrhythmias was associated with high plasma concentrations of troponin-T and N-terminal brain

237 plasma and 24 h urine sodium and potassium, plasma concentrations of TXB2 (stable TXA2 metabolite) a

238 Although initial plasma concentrations of U-50488 were higher in females,

239 Plasma concentrations of VEGF-A, VEGF-C, Ang1, and Ang2

240 k syndrome and sepsis), we sought to analyze plasma concentrations of VEGFs and Angs in patients with

241 Serum and plasma concentrations of vitamin B-12, holotranscobalami

242 peripheral neuropathy in elders with normal plasma concentrations of vitamin B-12.

243 We determined whether dietary intakes and plasma concentrations of vitamin C were associated with

244 d cediranib area under the curve and maximum plasma concentration on the daily, but not intermittent,

245 cally significant difference in piperacillin plasma concentrations over time between groups.

246 centration was significantly associated with plasma concentration (P < .001) and cytochrome P450 2B6

247 d glutamine de novo synthesis (P < 0.02) and plasma concentrations (P < 0.03) in both fasting and fed

248 tudy was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin

249 At the decitabine 0.16 mg/kg dose, plasma concentrations peaked at approximately 50 nM (Cma

250 e (using a dose that reproduced stress-level plasma concentrations) potentiated cocaine-primed reinst

251 ld male R92Q mice, ranolazine at therapeutic plasma concentrations prevented the development of HCM-r

252 nfusion over 24 hours had the most favorable plasma concentration profile.

253 gnificant increase in the leptin:adiponectin plasma concentration ratio in rats subjected to coronary

254 (range, n = 5) rilpivirine cord-to-maternal plasma concentration ratio was 0.50 (range, .35-.81).

255 The median time-averaged milk-to-plasma concentration ratio was 1.10 (range: 0.57-1.71).

256 OM exerted plasma concentration-related increases in left ventricul

257 lity and hunger ratings, motilin and ghrelin plasma concentrations, satiety, and caloric intake.Women

258 at BUP, NBUP, and MET at clinically relevant plasma concentrations significantly induced BCRP mRNA up

259 ic risk of Lp(a) is associated with elevated plasma concentration, small isoforms of apolipoprotein [

260 plasma concentration and fractional time of plasma concentration spent over 64 mg/L (4-fold the mini

261 entricular volumes that correlated with peak plasma concentrations, supporting a temporal association

262 ke palmitoylethanolamide, oleoylethanolamide plasma concentrations tended to be higher in nonhedonic

263 0.001) and an earlier time to reach maximal plasma concentration than that of cis isomers (28 +/- 7

264 ovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fuma

265 lar injection provides more rapid and higher plasma concentrations than subcutaneous routes.

266 spects of the use of these low doses and low plasma concentrations that require special attention.

267 lation to therapeutically relevant doses and plasma concentrations, there are specific aspects of the

268 th dosing regimens would reach target 3-hour plasma concentrations throughout the duration of the pre

269 Overall area under the plasma concentration-time curve (AUC) and plasma concent

270 platin continuous infusion of area under the plasma concentration-time curve 4.1 mg/mL per min per da

271 56 mg/m(2) resulted in higher area under the plasma concentration-time curve from time zero to last s

272 Methods: Plasma concentration-time data from 214 adult critically

273 Plasma concentration-time data from 214 adult critically

274 uated by the observed initial burst release, plasma concentration-time profiles, time at which maximu

275 icals and their metabolites to reach maximal plasma concentrations (Tmax) should be synchronised with

276 plied to individual compounds predicted fish plasma concentrations to be below the level of human the

277 onsteroidal anti-inflammatory drugs but with plasma concentrations too low to disrupt PG biosynthesis

278 We hypothesized that plasma concentration variability would expose the critic

279 Simulated median (interquartile range) day 7 plasma concentration was 29.4 (19.3-44.3) ng/ml in small

280 Piperacillin plasma concentration was measured every 12 hours over a

281 rutinib clinical trial revealed that exosome plasma concentration was significantly decreased followi

282 The plasma concentration was significantly increased in rena

283 /PD) analysis in patients with isavuconazole plasma concentrations was conducted to establish the exp

284 The fish plasma model (FPM), which predicts plasma concentrations, was applied to evaluate the poten

285 Ratios of DTG CSF to total plasma concentration were similar to the unbound fractio

286 Geometric mean trough plasma concentrations were 0.302 mug/mL (95% CI 0.237-0.

287 in the WT/MCD and ob/control groups, whereas plasma concentrations were 4.8-fold higher in ob/MCD mic

288 ety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24.

289 Infant plasma concentrations were highest up to 8 days of age a

290 Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured after last DCB deplo

291 Child PFAS plasma concentrations were not associated with leptin or

292 Prenatal PFAS plasma concentrations were not associated with leptin, a

293 Plasma concentrations were obtained from 9,183 patients,

294 SAHA plasma concentrations were similar to those achieved in

295 Metformin plasma concentrations were slightly increased in the WT/

296 more severe HF, as defined by high NT-proBNP plasma concentration, were at increased risk of VTE.

297 C-labeled total lycopene and lycopene-isomer plasma concentrations, which were measured with the use

298 he temporal profile of ghrelin or peptide YY plasma concentration with bedside functional assessment

299 pinephrine transporters that achieves stable plasma concentrations with once-daily dosing.

300 avir using a dosing regimen that resulted in plasma concentrations within the therapeutic range for c